Skip to content
Search

Latest Stories

Community pharmacy diabetes screening service could save NHS £50m each year - CCA report

Community pharmacy diabetes screening service could save NHS £50m each year - CCA report

Diabetes screening in community pharmacies could identify 45,000 undiagnosed cases of diabetes each year in England

A new report from the Company Chemists’ Association (CCA) is calling on NHS England to commission a community pharmacy-based national Type 2 diabetes screening service, which could save the NHS £50m each year.

The CCA report, titled Increasing Access to Diabetes Screening and Prevention Through Community Pharmacy’, highlights the urgent need for a national patient pathway for diabetes detection and management.


It outlines how NHS-commissioned diabetes screening in community pharmacies across England could deliver numerous health benefits each year, including:

  • Screening 1.5 million adults and identifying 180,000 prediabetics;
  • Detecting 45,000 undiagnosed cases of diabetes and preventing them from developing serious complications
  • Preventing nearly 7,000 heart attacks and strokes, and thus improving patients’ quality of life
  • Avoiding severe sight loss in around 15,000 people over their lifetime
  • Saving the NHS £50 million annually by reducing diabetes-related costs.

Type 2 diabetes and its complications are currently estimated to account for 10 per cent of the NHS annual budget, and this figure is projected to rise to 17 per cent by 2035/36.

In addition to its impact on healthcare, diabetes places a significant economic burden on society, with productivity losses and diabetes-related disabilities costing the UK over £20 billion each year.

Malcolm Harrison, CEO of the CCA, stated: “With the burden of Type 2 diabetes set to grow significantly, commissioning pharmacies to deliver a national diabetes screening service makes sense for patients, the NHS, and the UK economy.”

With around four million people diagnosed with diabetes across the UK and an additional two million at high risk, the report emphasises that community pharmacies are ideally positioned to help alleviate the strain on GP services.

Long waiting times for GP appointments and the need for patients to travel significant distances for care are major barriers to early detection, particularly in deprived areas.

The CCA estimates that 25 million GP appointments annually are dedicated to managing Type 2 diabetes, equivalent to a month’s worth of appointments.

The CCA is now urging NHS England to take three key actions:

  1. Commission a national diabetes screening service in community pharmacies.
  2. Improve IT communication between pharmacies and GP surgeries to streamline test result sharing.
  3. Develop patient pathways for newly diagnosed diabetics to access treatment through community pharmacies.

Data released by the National Diabetes Audit on June 12 indicated that the number of people in England identified as at risk for type 2 diabetes mellitus has increased by over half a million within a year.

It showed that 3.6 million people registered with a GP have non-diabetic hyperglycaemia (also known as pre-diabetes) in 2023, compared with 3.1 million people in 2022 — a notable 18 per cent increase or nearly 550,000 people.

More For You

Empty pharmacy shelves due to UK medicine shortages.

The government has said it's investing up to £520m to manufacture more medicines

Pic credit: iStock

Brexit blamed for UK medicine shortages with "little sign of recovery"

The UK is facing “a worsening situation” with drugs shortages compared to the rest of Europe as a result of Brexit, according to the Nuffield Trust health thinktank.

It comes of the back of data that revealed that the department of health and social care (DHSC) received 1,938 notifications of disruptions to medicine supply last year – the highest in four years.

Keep ReadingShow less
Alert! Patients on Promixin should be switched to alternatives by 30 April

Promixin is licensed for treating chronic pulmonary infections caused by Pseudomonas aeruginosa in adults and children with cystic fibrosis

Getty Images

Medicine shortage: Promixin to be discontinued from May 2025

The Department of Health and Social Care (DHSC) and NHS England have issued a national patient safety alert regarding the upcoming shortage of Promixin (colistimethate).

The alert, issued on 17 March 2025, states that Promixin (colistimethate) 1-million-unit powder for nebuliser solution unit dose vials (UDVs) will be discontinued from early May 2025, with stocks expected to be exhausted by this time.

Keep ReadingShow less
PAGB welcomes new vice-presidents and treasurer to Board

Rob Elliott and Bas Vorsteveld ( L-R)

Bas Vorsteveld will now oversee the Kenvue’s business in Northern Europe

PAGB appoints new vice-presidents and treasurer to Board

PAGB, the consumer healthcare association, has announced the appointment of two new vice-presidents and a treasurer to their Board.

Bas Vorsteveld, area managing director for Northern Europe at Kenvue, and Rob Elliott, OTC centre of excellence lead at Viatris, have been elected as vice-presidents.

Keep ReadingShow less
Omega Pharmacy in Derbyshire Finds New Owner in Just 18 Days

Omega Pharmacy

Christie & Co

Omega Pharmacy in Derbyshire sold in just 18 days

Omega Pharmacy in Derbyshire has found a new owner in less than three weeks after being put on the market.

The pharmacy was previously owned by husband-and-wife duo Manny and Poonam Rai, who decided to sell it after a short period of ownership to focus on their other pharmacy in Coventry, according to Christie & Co.

Keep ReadingShow less
DHSC announces second list of March 2025 price concessions

A price concession only applies for the month it is granted.

Getty Images

March price concessions list released; prescription charge remains unchanged

The Department of Health and Social Care (DHSC) has released a second list of price concessions for March 2025, following ongoing discussions with Community Pharmacy England (CPE) regarding medicine pricing concerns raised by pharmacy owners.

A price concession is introduced when pharmacy contractors are unable to source a drug at or below the reimbursement price set out in the Drug Tariff.

Keep ReadingShow less